Urso, L.; Panareo, S.; Castello, A.; Ambrosio, M.R.; Zatelli, M.C.; Caracciolo, M.; Tonini, E.; Valpiani, G.; Boschi, A.; Uccelli, L.;
et al. Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial. Pharmaceutics 2022, 14, 2009.
https://doi.org/10.3390/pharmaceutics14102009
AMA Style
Urso L, Panareo S, Castello A, Ambrosio MR, Zatelli MC, Caracciolo M, Tonini E, Valpiani G, Boschi A, Uccelli L,
et al. Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial. Pharmaceutics. 2022; 14(10):2009.
https://doi.org/10.3390/pharmaceutics14102009
Chicago/Turabian Style
Urso, Luca, Stefano Panareo, Angelo Castello, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Matteo Caracciolo, Eugenia Tonini, Giorgia Valpiani, Alessandra Boschi, Licia Uccelli,
and et al. 2022. "Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial" Pharmaceutics 14, no. 10: 2009.
https://doi.org/10.3390/pharmaceutics14102009
APA Style
Urso, L., Panareo, S., Castello, A., Ambrosio, M. R., Zatelli, M. C., Caracciolo, M., Tonini, E., Valpiani, G., Boschi, A., Uccelli, L., Cittanti, C., & Bartolomei, M.
(2022). Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial. Pharmaceutics, 14(10), 2009.
https://doi.org/10.3390/pharmaceutics14102009
